Vieira Barbosa Joana, Fraga Montserrat, Saldarriaga Joan, Hiroz Philippe, Giostra Emiliano, Sempoux Christine, Ferenci Peter, Moradpour Darius
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.
Institute of Pathology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland.
Swiss Med Wkly. 2018 Dec 21;148:w14699. doi: 10.4414/smw.2018.14699. eCollection 2018 Dec 17.
Wilson’s disease is an inherited disorder of hepatic copper metabolism, leading to the accumulation of copper in the liver as well as the brain, cornea and other organs. Here, we describe the adult cases of hepatic Wilson’s disease diagnosed at the Division of Gastroenterology and Hepatology of the University Hospital Lausanne, Switzerland between September 2004 and August 2016.
Clinical manifestations, results of diagnostic tests, management and outcomes of adult patients with hepatic Wilson’s disease were assessed based on standardised medical records. In addition, liver histology was reviewed and the lesional patterns were recorded.
Ten new adult cases of hepatic Wilson’s disease were diagnosed in our centre between September 2004 and August 2016. Male to female ratio was 1:1 and median age at diagnosis was 26 (range 18–56) years. Four patients presented with acute liver failure, four with persistently elevated liver function tests, and two with decompensated cirrhosis; none had neurological manifestations. Only one patient had a Kayser-Fleischer corneal ring. Median ceruloplasmin level at diagnosis was 0.13 (range <0.03–0.30) g/l, median 24-hour urinary copper excretion was 2.8 (range 0.3–77.3) μmol, and median hepatic copper concentration was 789 (range 284–1677) μg/g. At least one mutation in the ATP7B gene was identified in eight patients. Allelic frequency of the common H1069Q mutation was 19%. Leipzig score was ≥5 in all patients. Three patients presenting with acute liver failure and the two with decompensated cirrhosis underwent successful liver transplantation. One patient with acute liver failure recovered under chelation therapy, as predicted by a Dhawan score <11. D-penicillamine was used as first-line chelator treatment, with a subsequent switch to trientine due to adverse effects in three out of six patients.
The clinical presentation of hepatic Wilson’s disease is highly variable. Three out of 10 patients were diagnosed at an age >35 years. A high index of suspicion in clinically compatible situations is key.
威尔逊病是一种遗传性肝铜代谢紊乱疾病,会导致铜在肝脏以及脑、角膜和其他器官中蓄积。在此,我们描述了2004年9月至2016年8月期间在瑞士洛桑大学医院胃肠病学和肝病科确诊的成人肝威尔逊病病例。
基于标准化病历评估成人肝威尔逊病患者的临床表现、诊断检查结果、治疗及预后。此外,对肝脏组织学进行回顾并记录病变模式。
2004年9月至2016年8月期间,我们中心确诊了10例新的成人肝威尔逊病病例。男女比例为1:1,诊断时的中位年龄为26岁(范围18 - 56岁)。4例患者表现为急性肝衰竭,4例肝功能检查持续升高,2例为失代偿性肝硬化;均无神经学表现。仅1例患者有凯-弗环。诊断时血浆铜蓝蛋白水平中位数为0.13 g/l(范围<0.03 - 0.30 g/l),24小时尿铜排泄量中位数为2.8 μmol(范围0.3 - 77.3 μmol),肝铜浓度中位数为789 μg/g(范围284 - 1677 μg/g)。8例患者中至少鉴定出ATP7B基因的一个突变。常见的H1069Q突变的等位基因频率为19%。所有患者的莱比锡评分≥5分。3例急性肝衰竭患者和2例失代偿性肝硬化患者接受了成功的肝移植。1例急性肝衰竭患者在螯合治疗下康复,达万评分<11分提示了这一结果。青霉胺用作一线螯合剂治疗,6例患者中有3例因不良反应随后改用曲恩汀。
肝威尔逊病的临床表现高度多变。10例患者中有3例在35岁以上确诊。在临床情况相符时保持高度怀疑指数是关键。